Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9842152 | 0.91 | IDO1 (0.64) | IDO1MAOBKCNH2EGLN1TSHR | |
| SCHEMBL12266469 | 0.87 | IDO1 (0.60) | IDO1MAOBKCNH2EGLN1RAB9A | |
| SCHEMBL6667381 | 0.87 | IDO1 (0.69) | IDO1MAOBKCNH2EGLN1TSHR | |
| SCHEMBL9283193 | 0.85 | TSHR (0.62) | IDO1MAOBKCNH2TSHRAR | |
| Hydroquinone SCHEMBL10866249 | 0.83 | IDO1 (0.60) | IDO1MAOBEGLN1TSHRAR | |
| SCHEMBL13170339 | 0.83 | IDO1 (0.60) | IDO1MAOBCHRM3ARTAAR1 | |
| SCHEMBL14437517 | 0.83 | MAOB (0.66) | IDO1MAOBMAOAACHE | |
| SCHEMBL30398600 | 0.83 | MAOB (0.66) | IDO1MAOBMAOAACHE | |
| SCHEMBL8589839 | 0.81 | IDO1 (0.50) | IDO1MAOBEGLN1CHRM3TSHR | |
| SCHEMBL10735 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, CCNB2 | IDO1 3268/4885MAOB 3101/4885KCNH2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.